Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial

Rafael León López, Sheila Cárcel Fernández, Laura Limia Pérez, Alberto Romero Palacios, María Concepción Fernández-Roldán, Eduardo Aguilar Alonso, Inés Pérez Camacho, Jesús Rodriguez-Baño, Nicolás Merchante, Julián Olalla, M Ángeles Esteban-Moreno, Marta Santos, Antonio Luque-Pineda, Julian Torre-Cisneros, Rafael León López, Sheila Cárcel Fernández, Laura Limia Pérez, Alberto Romero Palacios, María Concepción Fernández-Roldán, Eduardo Aguilar Alonso, Inés Pérez Camacho, Jesús Rodriguez-Baño, Nicolás Merchante, Julián Olalla, M Ángeles Esteban-Moreno, Marta Santos, Antonio Luque-Pineda, Julian Torre-Cisneros

Abstract

Introduction: About 25% of patients with COVID-19 develop acute respiratory distress syndrome (ARDS) associated with a high release of pro-inflammatory cytokines such as interleukin-6 (IL-6). The aim of the SARICOR study is to demonstrate that early administration of sarilumab (an IL-6 receptor inhibitor) in hospitalised patients with COVID-19, pulmonary infiltrates and a high IL-6 or D-dimer serum level could reduce the progression of ARDS requiring high-flow nasal oxygen or mechanical ventilation (non-invasive or invasive).

Methods and analysis: Phase II, open-label, randomised, multicentre, controlled clinical trial to study the efficacy and safety of the administration of two doses of sarilumab (200 and 400 mg) plus best available therapy (BAT) in hospitalised adults with COVID-19 presenting cytokine release syndrome. This strategy will be compared with a BAT control group. The efficacy and safety will be monitored up to 28 days postadministration. A total of 120 patients will be recruited (40 patients in each arm).

Ethics and dissemination: The clinical trial has been approved by the Research Ethics Committee of the coordinating centre and authorised by the Spanish Agency of Medicines and Medical Products. If the hypothesis is verified, the dissemination of the results could change clinical practice by increasing early administration of sarilumab in adult patients with COVID-19 presenting cytokine release syndrome, thus reducing intensive care unit admissions.

Trial registration number: NCT04357860.

Keywords: adult intensive & critical care; infectious diseases; internal medicine; virology.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Flow diagram. BAT, best available therapy.

References

    1. Wang J, Jiang M, Chen X, et al. . Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J Leukoc Biol 2020;108:17–41. 10.1002/JLB.3COVR0520-272R
    1. Hamming I, Timens W, Bulthuis MLC, et al. . Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004;203:631–7. 10.1002/path.1570
    1. Cheng H, Wang Y, Wang G-Q. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19. J Med Virol 2020;92:726–30. 10.1002/jmv.25785
    1. Laing AG, Lorenc A, Barrio DMD, et al. . A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat Med 2020.
    1. Ackermann M, Verleden SE, Kuehnel M, et al. . Pulmonary vascular Endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med 2020;383:120–8. 10.1056/NEJMoa2015432
    1. Henry BM, de Oliveira MHS, Benoit S, et al. . Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med 2020;58:1021–8. 10.1515/cclm-2020-0369
    1. Li S, Jiang L, Li X, et al. . Clinical and pathological investigation of patients with severe COVID-19. JCI Insight 2020;5:e138070 10.1172/jci.insight.138070
    1. Ascierto PA, Fox BA, Urba WJ, et al. . Insights from immuno-oncology: the Society for immunotherapy of cancer statement on access to IL-6-targeting therapies for COVID-19. J Immunother Cancer 2020;8:e000878. 10.1136/jitc-2020-000878
    1. Huang C, Wang Y, Li X, et al. . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506. 10.1016/S0140-6736(20)30183-5
    1. Sarzi-Puttini P, Giorgi V, Sirotti S, et al. . COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? Clin Exp Rheumatol 2020;38:337–42.
    1. Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res 2020;81:537–40. 10.1002/ddr.21656
    1. Vaduganathan M, Vardeny O, Michel T, et al. . Renin-Angiotensin-Aldosterone system inhibitors in patients with Covid-19. N Engl J Med 2020;382:1653–9. 10.1056/NEJMsr2005760
    1. Zhang X, Li S, Niu S. Ace2 and COVID-19 and the resulting ARDS. Postgrad Med J 2020;96:403–7. 10.1136/postgradmedj-2020-137935
    1. Benetti E, Tita R, Spiga O, et al. . Ace2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population. Eur J Hum Genet 2020;17:1–13. 10.1038/s41431-020-0691-z
    1. Cytokine storm drugs move from CAR T to COVID-19. Cancer Discov 2020;10:OF8 10.1158/-ND2020-008
    1. Köhler BM, Günther J, Kaudewitz D, et al. . Current therapeutic options in the treatment of rheumatoid arthritis. J Clin Med 2019;8:938 10.3390/jcm8070938
    1. Chen X, Zhao B, Qu Y, et al. . Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. Clin Infect Dis 2020:ciaa449. 10.1093/cid/ciaa449
    1. SIMIT Interpretation of “New Coronavirus Pneumonia Diagnosis and Treatment Scheme (Trial Version 7)” 2020. Vademecum per la cura delle persone con malattia da COVI-19. 39 SIMIT, 2020.
    1. Maggi E, Canonica GW, Moretta L. COVID-19: unanswered questions on immune response and pathogenesis. J Allergy Clin Immunol 2020;146:18–22. 10.1016/j.jaci.2020.05.001
    1. Sinha P, Matthay MA, Calfee CS. Is a "Cytokine Storm" Relevant to COVID-19? JAMA Intern Med 2020.
    1. Wilson JG, Simpson LJ, Ferreira A-M, et al. . Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis. JCI Insight 2020;5 10.1172/jci.insight.140289
    1. Murthy S, Gomersall CD, Fowler RA. Care for critically ill patients with COVID-19. JAMA 2020;323:1499–500. 10.1001/jama.2020.3633
    1. Xie J, Tong Z, Guan X, et al. . Critical care crisis and some recommendations during the COVID-19 epidemic in China. Intensive Care Med 2020;46:837–40. 10.1007/s00134-020-05979-7
    1. Liu D, Ahmet A, Ward L, et al. . A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol 2013;9:30.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa